ZNF503 and cancer: There was also a positive correlation between ZNF503-AS2 and most of the steps in the cancer immune cycle (Fig 4H), which may be helpful for improving antitumor immunity, and immunogenic cell death (ICD)-related genes associated with immunotherapy were also differentially expressed between the two groups (Fig 4I).